The miR-487b-3p/GRM3/TGFβ signaling axis is an important regulator of colon cancer tumorigenesis
Authors:
Open Access
- 23 January 2017
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 36 (24) , 3477-3489
Abstract
Molecular targeting is an import strategy to treat advanced colon cancer. The current study demonstrates that expression of GRM3, a metabotropic glutamate receptor mainly expressed in mammalian central nervous system, is significantly upregulated in majority of human colonic adenocarcinomas tested and colon cancer cell lines. Knockdown of GRM3 expression or inhibition of GRM3 activation in colon cancer cells reduces cell survival and anchorage-independent growth in vitro and inhibits tumor growth in vivo. Mechanistically, GRM3 antagonizes TGFβ-mediated activation of protein kinase A and inhibition of Protein kinase B (AKT). In addition, TGFβ signaling increases GRM3 protein stability and knockdown of GRM3 enhances TGFβ-mediated tumor suppressor function. Further studies indicate that miR-487b-3p directly targets GRM3. Overexpression of miR-487b-3p mimics the effects of GRM3 knockdown and suppresses the tumorigenicity of colon cancer cells in vivo. Expression of miR-487b-3p is decreased in colon adenocarcinomas and inversely correlates with GRM3 expression. Taken together, these studies indicate that upregulation of GRM3 expression is a functionally important molecular event in colon cancer, and that GRM3 is a promising molecular target for colon cancer treatment. This is particularly interesting and important from a therapeutic standpoint because numerous metabotropic glutamate receptor antagonists are available, many of which have been found unsuitable for treatment of neuropsychiatric disorders for reasons such as inability to readily penetrate blood brain barriers. As GRM3 is upregulated in colon cancer, but rarely expressed in normal peripheral tissues, targeting GRM3 with such agents would not likely cause adverse neurological or peripheral side effects, making GRM3 an attractive and specific molecular target for colon cancer treatment.Keywords
This publication has 57 references indexed in Scilit:
- TGF-Beta Suppresses VEGFA-Mediated Angiogenesis in Colon Cancer MetastasisPLOS ONE, 2013
- Transcriptional regulation of the chemokine co-receptor CCR5 by the cAMP/PKA/CREB pathwayBiomedicine & Pharmacotherapy, 2011
- TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective studyBMC Cancer, 2007
- MicroRNA Targeting Specificity in Mammals: Determinants beyond Seed PairingMolecular Cell, 2007
- TGF-β signaling: positive and negative effects on tumorigenesisCurrent Opinion in Genetics & Development, 2002
- CDX2 is mutated in a colorectal cancer with normal APC/β-catenin signalingOncogene, 1999
- Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease geneProceedings of the National Academy of Sciences, 1998
- Reduced Expression of Transforming Growth Factor β Type I Receptor Contributes to the Malignancy of Human Colon Carcinoma CellsJournal of Biological Chemistry, 1996
- Signal transduction and pharmacological characteristics of a metabotropic glutamate receptor, mGluRl, in transfected CHO cellsNeuron, 1992
- A family of metabotropic glutamate receptorsNeuron, 1992